Keyphrases
Tyrosine Kinase Inhibitor
100%
Tivozanib
100%
Kidney Cancer
100%
Vascular Endothelial Growth Factor
100%
Clinical Significance
66%
Tumor Subtype
66%
Long Half-life
66%
Market Relevance
66%
Clinical Efficacy
33%
Mammalian Target of Rapamycin (mTOR)
33%
Renal Cell Carcinoma
33%
Treatment Options
33%
Drug Development
33%
Sorafenib
33%
Sunitinib
33%
U.S. Food
33%
Pazopanib
33%
Targeted Agents
33%
Expert Opinion
33%
High Potency
33%
Drug Evaluation
33%
Ongoing Development
33%
Off-target Effects
33%
Evaluation Review
33%
Dose Combination
33%
Area Cover
33%
Advanced RCC
33%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase Inhibitor
100%
Vasculotropin
100%
Tivozanib
100%
Kidney Cancer
100%
Neoplasm
66%
Drug Development
33%
Drug Screening
33%
Receptor
33%
Sorafenib
33%
Renal Cell Carcinoma
33%
Pazopanib
33%
Mammalian Target of Rapamycin
33%
Sunitinib
33%